Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mapping lifelong chronic health risks for childhood cancer survivors

2.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

3.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

4.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

5.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot